Matt Miksic
Stock Analyst at Barclays
(0.43)
# 3,937
Out of 4,825 analysts
276
Total ratings
n/a
Success rate
-6.84%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Equal-Weight | $234 → $266 | $251.59 | +5.73% | 8 | Apr 30, 2025 | |
| INMD InMode | Maintains: Overweight | $29 → $24 | $14.75 | +62.77% | 13 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $118 → $125 | $103.19 | +21.14% | 17 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $684 → $635 | $517.18 | +22.78% | 7 | Apr 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $166 → $165 | $154.46 | +6.82% | 12 | Apr 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $158 → $159 | $130.88 | +21.49% | 29 | Apr 17, 2025 | |
| BAX Baxter International | Maintains: Overweight | $39 → $41 | $30.67 | +33.68% | 21 | Mar 10, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $58 → $56 | $36.84 | +52.03% | 6 | Mar 7, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $60 → $53 | $19.98 | +165.27% | 6 | Feb 28, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $103 | $71.12 | +44.83% | 14 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $90 | $75.33 | +19.47% | 28 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $101.94 | +9.87% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $373.99 | +18.45% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $11.13 | +88.76% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.71 | +367.09% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $16 | $2.78 | +476.58% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $83.56 | +30.45% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $138 → $113 | $70.26 | +60.83% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $9.04 | +76.99% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $18 | $11.59 | +55.31% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $96.17 | -0.18% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $64.46 | +55.13% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $176.74 | +136.51% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $12.09 | +131.69% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $13.94 | +380.80% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $7.95 | +5,937.74% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $16.43 | +429.52% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.97 | +403.52% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.35 | +41.84% | 1 | Dec 12, 2016 |
Insulet
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $234 → $266
Current: $251.59
Upside: +5.73%
InMode
Apr 30, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $14.75
Upside: +62.77%
Boston Scientific
Apr 25, 2025
Maintains: Overweight
Price Target: $118 → $125
Current: $103.19
Upside: +21.14%
Intuitive Surgical
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $517.18
Upside: +22.78%
Johnson & Johnson
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $166 → $165
Current: $154.46
Upside: +6.82%
Abbott Laboratories
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $130.88
Upside: +21.49%
Baxter International
Mar 10, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $30.67
Upside: +33.68%
LivaNova
Mar 7, 2025
Maintains: Equal-Weight
Price Target: $58 → $56
Current: $36.84
Upside: +52.03%
Tandem Diabetes Care
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $19.98
Upside: +165.27%
Globus Medical
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $71.12
Upside: +44.83%
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $75.33
Upside: +19.47%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $101.94
Upside: +9.87%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $373.99
Upside: +18.45%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $11.13
Upside: +88.76%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.71
Upside: +367.09%
Jan 2, 2025
Initiates: Overweight
Price Target: $16
Current: $2.78
Upside: +476.58%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $83.56
Upside: +30.45%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $138 → $113
Current: $70.26
Upside: +60.83%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $9.04
Upside: +76.99%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $11.59
Upside: +55.31%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $96.17
Upside: -0.18%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $64.46
Upside: +55.13%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $176.74
Upside: +136.51%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $12.09
Upside: +131.69%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $13.94
Upside: +380.80%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $7.95
Upside: +5,937.74%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $16.43
Upside: +429.52%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.97
Upside: +403.52%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.35
Upside: +41.84%